Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-08-10Clinical Trial Update: Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating biomarker strategies for medication-enhanced cognitive training in schizophrenia has completed enrollm…
-
EMA approval · 2020-07-31EMA Authorised: Olazax (olanzapine) — Glenmark Pharmaceuticals s.r.o.
Olazax (olanzapine) has been authorised for schizophrenia and bipolar disorder in the European Union.
-
FDA approval · 2020-07-29FDA Approved: VERSACLOZ — Supplemental Application (TruPharma LLC)
FDA approved a supplemental application for Versacloz (clozapine) submitted by TruPharma LLC.
-
FDA approval · 2020-07-26FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental ANDA for Clozapine from Mylan Pharmaceuticals, approving a generic version of Clozapine under ANDA 201824.
-
CLINICAL_TRIALS trial_result · 2020-07-16Clinical Trial Update: A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic [Phase 4]
Phase 4 trial evaluating acceptance and performance of a digital medicine system for adults with schizophrenia, schizoaffective disorder, or…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-07-09FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved the generic version of fluphenazine hydrochloride (Amneal) through an original ANDA, for the treatment of schizophrenia.
-
FDA approval · 2020-07-07FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Original Application (Eugia US LLC)
The FDA approved Eugia US LLC's generic chlorpromazine hydrochloride under an Original Application (ANDA 211816).
-
CLINICAL_TRIALS research · 2020-06-19Clinical Trial Update: Bergen Psychosis Project 2 - The Best Intro Study [Phase 4]
Phase 4 clinical trial update for the Bergen Psychosis Project 2, a post-approval or post-market study related to schizophrenia and psychoti…
-
CLINICAL_TRIALS trial_result · 2020-06-18Clinical Trial Update: DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole [Phase 4]
Phase 4 clinical trial update for a digital medicine study in adults using aripiprazole for schizophrenia, major depressive disorder, or bip…
-
CLINICAL_TRIALS trial_result · 2020-06-17Clinical Trial Update: Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1) [Phase 3]
A Phase 3 clinical trial assessing the efficacy and safety of adjunctive pimavanserin for schizophrenia has completed and results were poste…
-
EMA approval · 2020-06-16EMA Authorised: Olazax Disperzi (olanzapine) — Glenmark Pharmaceuticals s.r.o.
Authorised olazax disperzi (olanzapine) for schizophrenia and bipolar disorder in the EU.
-
CLINICAL_TRIALS trial_result · 2020-06-02Clinical Trial Update: PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations [NA]
Clinical trial update for a PET imaging study in Amish and Mennonite patients with CNTNAP2 mutations related to schizophrenia; study termina…
-
CLINICAL_TRIALS trial_result · 2020-05-26Clinical Trial Update: Estradiol as add-on to Antipsychotics [Phase 3]
Phase 3 clinical trial update investigating estradiol as an add-on treatment to antipsychotics for schizophrenia-spectrum disorders.
-
CLINICAL_TRIALS trial_result · 2020-05-22Clinical Trial Update: Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder [Phase 3]
A Phase 3 clinical trial evaluated estradiol patch as an add-on to antipsychotics for schizophrenia and related disorders; the study has com…
-
CLINICAL_TRIALS trial_result · 2020-05-12Clinical Trial Update: Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700 [Phase 1]
Phase 1 PET study assessing dopamine and serotonin receptor occupancy after multiple oral dosing of Lu AF35700 in schizophrenia; study compl…
-
CLINICAL_TRIALS trial_result · 2020-05-08Clinical Trial Update: A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia [Phase 1]
Phase 1 study to determine the maximum tolerated dose of an investigational drug in adults with schizophrenia; study completed with results …
-
CLINICAL_TRIALS trial_result · 2020-05-06Clinical Trial Update: Brief Group Psychoeducation for Schizophrenia [NA]
A completed clinical trial evaluating brief group psychoeducation for schizophrenia; results posted in 2020.
-
FDA approval · 2020-04-23FDA Approved: ZYPREXA RELPREVV — Supplemental Application (H2-Pharma LLC)
The FDA approved a supplemental application for ZYPREXA RELPREVV (olanzapine pamoate) submitted by H2-Pharma LLC.
-
FDA approval · 2020-04-23FDA Approved: ZYPREXA ZYDIS — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for ZYPREXA ZYDIS (olanzapine) submitted by Eli Lilly and Company.
-
FDA approval · 2020-04-22FDA Approved: ZYPREXA RELPREVV — Supplemental Application (H2-Pharma LLC)
The FDA approved a supplemental application for ZYPREXA RELPREVV (olanzapine pamoate) submitted by H2-Pharma LLC.
-
FDA approval · 2020-04-21FDA Approved: ZYPREXA INTRAMUSCULAR — Supplemental Application (Eli Lilly and Company)
The FDA approved Eli Lilly's supplemental application for ZYPREXA Intramuscular (olanzapine), finalizing approval for the intramuscular form…
-
FDA approval · 2020-04-21FDA Approved: ZYPREXA ZYDIS — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for ZYPREXA ZYDIS (olanzapine) submitted by Eli Lilly and Company, related to the orodispersible tab…
-
FDA approval · 2020-04-21FDA Approved: ZYPREXA RELPREVV — Supplemental Application (H2-Pharma LLC)
FDA approved a supplemental application for ZYPREXA RELPREVV (olanzapine pamoate) from H2-Pharma LLC, authorizing changes to its regulatory …
-
CLINICAL_TRIALS trial_result · 2020-04-20Clinical Trial Update: Antipsychotic Effects on Brain Function in Schizophrenia [Phase 4]
Phase 4 trial update on antipsychotic effects on brain function in schizophrenia and related disorders; study terminated with posted results…
-
FDA approval · 2020-04-14FDA Approved: CLOZARIL — Supplemental Application (HLS Therapeutics (USA), Inc.)
The FDA approved a supplemental application for Clozaril (clozapine) submitted by HLS Therapeutics (USA), Inc., likely updating or expanding…